Abstract
The treatment of brain tumors and neurodegenerative diseases, represents an ongoing challenge. In Central Nervous System (CNS) the achievement of therapeutic concentration of chemical agents is complicated by the presence of distinct set of efflux proteins, such as ATP-Binding Cassette (ABC) transporters localized on the Blood-Brain Barrier (BBB). The activity of ABC transporters seems to be a common mechanism that underlies the poor response of CNS diseases to therapies.
The molecular characterization of Breast Cancer Resistance Protein (BCRP/ABCG2), as an ABC transporter conferring multidrug resistance (MDR), has stimulated many studies to investigate its activity on the BBB, its involvement in physiology and CNS diseases and its role in limiting the delivery of drugs in CNS.
In this review, we highlight the activity and localization of BCRP on the BBB and the action that this efflux pump has on many conventional drugs or latest generation molecules used for the treatment of CNS tumors and other neurodegenerative diseases.
Keywords: BCRP, Blood-Brain Barrier, brain tumors, multidrug resistance, neurodegenerative diseases.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Volume: 16 Issue: 7
Author(s): Anna Lisa Iorio, Martina da Ros, Ornella Fantappiè, Maurizio Lucchesi, Ludovica Facchini, Alessia Stival, Sabrina Becciani, Milena Guidi, Claudio Favre, Maurizio de Martino, Lorenzo Genitori and Iacopo Sardi
Affiliation:
Keywords: BCRP, Blood-Brain Barrier, brain tumors, multidrug resistance, neurodegenerative diseases.
Abstract: The treatment of brain tumors and neurodegenerative diseases, represents an ongoing challenge. In Central Nervous System (CNS) the achievement of therapeutic concentration of chemical agents is complicated by the presence of distinct set of efflux proteins, such as ATP-Binding Cassette (ABC) transporters localized on the Blood-Brain Barrier (BBB). The activity of ABC transporters seems to be a common mechanism that underlies the poor response of CNS diseases to therapies.
The molecular characterization of Breast Cancer Resistance Protein (BCRP/ABCG2), as an ABC transporter conferring multidrug resistance (MDR), has stimulated many studies to investigate its activity on the BBB, its involvement in physiology and CNS diseases and its role in limiting the delivery of drugs in CNS.
In this review, we highlight the activity and localization of BCRP on the BBB and the action that this efflux pump has on many conventional drugs or latest generation molecules used for the treatment of CNS tumors and other neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Iorio Lisa Anna, Ros da Martina, Fantappiè Ornella, Lucchesi Maurizio, Facchini Ludovica, Stival Alessia, Becciani Sabrina, Guidi Milena, Favre Claudio, Martino de Maurizio, Genitori Lorenzo and Sardi Iacopo, Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (7) . https://dx.doi.org/10.2174/1871520616666151120121928
DOI https://dx.doi.org/10.2174/1871520616666151120121928 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry Computational Studies on the Histone Deacetylases and the Design of Selective Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Geminin as A Molecular Target for the Development of New Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Testosterone Based Esters as Inhibitors of Aromatase (AR) and the use of the Substrate-Haem Complex Approach in the Rationalisation of the Inhibitory Activity of these Compounds
Letters in Drug Design & Discovery Perspectives on Chemopreventive and Therapeutic Potential of Curcumin Analogs in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Design, Synthesis and Evaluation of Hybrid 2-Heteroaryl Benzimidazole- Chalcone Derivatives as Anticancer Agents
Letters in Organic Chemistry Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine Modulators of Networks: Molecular Targets of Arterial Calcification Identified in Man and Mice
Current Pharmaceutical Design Radiopharmaceutical: Revolutionary Agents for Diagnosis
Current Radiopharmaceuticals Extra-Hepatic Isozymes from the CYP1 and CYP2 Families as Potential Chemotherapeutic Targets
Current Topics in Medicinal Chemistry A Multiresolution Ripplet Transform for Breast Cancer Diagnosis in Digital Mammograms
Recent Patents on Computer Science Novel Therapeutic Strategies Against Cancer: Marine-derived Drugs May Be the Answer?
Anti-Cancer Agents in Medicinal Chemistry Phytochemicals: Key to Effective Anticancer Drugs
Mini-Reviews in Organic Chemistry Third Generation Radiopharmaceuticals for Imaging and Targeted Therapy
Current Pharmaceutical Analysis Quantifying Risk: The Role of Absolute and Relative Measures in Interpreting Risk of Adverse Reactions from Product Labels of Antipsychotic Medications
Current Drug Safety Molecular Bases of Chemoresistance in Cholangiocarcinoma
Current Drug Targets Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Design and Synthesis of Novel Coumarin Conjugated Acetamides as Promising Anticancer Agents: An <i>In Silico</i> and <i>In Vitro</i> Approach
Anti-Cancer Agents in Medicinal Chemistry